CGCaroline Hartwell Garred

Caroline Hartwell Garred

*This is an algorithmically generated author record based on publicly available information.

Caroline Hartwell Garred has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Modification of the association between age and mortality in heart failure by frailty status

    by Caroline Hartwell Garred, Mariam Elmegaard, Daniel Mølager Christensen, Clara Friis, Alexander Christian Falkentoft, Morten Malmborg, Deewa Zahir Anjum, Nina Nouhravesh, Jawad Butt, Jesper Ryg, et al.

    Aims: Heart failure (HF) disproportionately affects older patients, yet evidence guiding management in the oldest and frailest patients remains limited. We evaluated the influence of age and frailty on mortality and use of guideline-directed medical therapy (GDMT). Methods: Using nationwide Danish registry data, we identified all patients with new-onset HF (2013–22), stratified by age (<65, 65–79, ≥80 years) and frailty status according to the Hospital Frailty Risk Score (low, intermediate, high). We assessed all-cause and cardiovascular mortality 2 years after HF diagnosis and evaluated GDMT use across age and frailty groups using logistic regression. Results: Among 79 193 patients with HF, 24% were aged <65 years, 41% 65–79, and 35% ≥80. Frailty significantly modified the association between age and mortality (interaction P < .001). Patients with high frailty reached comparable 2-year mortality risks at younger ages than patients with lower frailty. The following had similar 2-year mortality: low-frailty patients aged 80 years (22.1%, 95% confidence interval, 21.4–22.8), intermediate-frailty patients aged 70 years (22.8%, 21.9–23.8), and high-frailty patients aged 47 (22.8%, 18.0–28.4). Similar results were seen for cardiovascular mortality. Guideline-directed medical therapy use was lower in high frailty than low-frailty patients across all age groups. Moreover, within each frailty group, patients aged ≥80 years had lower odds of receiving GDMT compared with those aged <65 (reference). Conclusion: Frailty alters mortality risk in HF beyond chronological age, resulting in prognostic heterogeneity regardless of age. Our findings support the need for both frailty-informed and age-based management strategies in HF across all ages.


  • Open Access

    Care and Outcomes of New‐Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022

    by Sofie‐Louise Feentved Ødum, Clara Friis, Caroline Hartwell Garred, Nina Nouhravesh, Deewa Zahir Anjum, Camilla Fuchs Andersen, Jesper Jensen, Emil Fosbøl, Lars Køber, Daniel Mølager Christensen, et al.

    Background: Heart failure (HF) prevalence is increasing. In a nationwide cohort study, we investigated temporal trends in care and outcomes of patients with new‐onset HF within vulnerable populations. Methods: There were 154 819 patients with new‐onset HF between 2003 and 2022 identified and included using Danish nationwide registries. Eight potentially vulnerable subgroups were defined (aged ≥80 years, women, low income, living alone, mental illness, non‐Western background, frail, and rural residency) and compared with their counterparts. Temporal trends in initiation of guideline‐recommended HF therapy and risk of all‐cause mortality were analyzed. Results: Initiation of guideline‐recommended HF therapies (mineralocorticoid‐receptor‐antagonists, β‐blockers, renin‐angiotensin system inhibitors) was generally successful, but initiation of mineralocorticoid receptor antagonists was insufficient in vulnerable patients. Five‐year all‐cause mortality decreased from 2003 to 2007 to 2018 to 2022; however, those aged ≥80 years, frail, and living alone experienced a smaller decrease (aged ≥80 years versus counterpart: adjusted hazard ratio [aHR], 0.74 [95% CI, 0.72–0.76] versus aHR, 0.63 [95% CI, 0.61–0.65]; frail versus counterpart: aHR, 0.74 [95% CI, 0.71–0.77] versus aHR, 0.67 [95% CI, 0.65–0.68]; living alone versus counterpart: aHR, 0.75 [95% CI, 0.73–0.77] versus aHR, 0.62 [95% CI, 0.60–0.64]); and patients with mental illness experienced no improvements (mental illness versus counterpart: aHR, 0.99 [95% CI, 0.87–1.12] versus aHR, 0.68 [95% CI, 0.67–0.70]). Six vulnerable groups had higher aHRs compared with their counterparts in 2018 to 2022. Conclusions: Initiation of guideline‐recommended therapies improved over the past 2 decades, but initiation of mineralocorticoid receptor antagonists was inadequate in vulnerable patients. Furthermore, the overall mortality risk declined, but 4 out of the 8 vulnerable groups experienced a lesser decline than their counterparts. Despite improvements, 6 vulnerable groups still had worse outcomes than their counterparts at the end of the study period. Our findings highlight the urgent need for more effort aimed at helping vulnerable subgroups of patients with HF.

  • Trends in Guideline-Directed Medical Therapies and Clinical Management in Patients With Prevalent Versus Incident Heart Failure: A Danish Nationwide Study From 1996 to 2022

    by Emma Kidholm Boysen, Lars Køber, Mads Kristian Ersbøll, Trine Kiilerich Lauridsen, Jesper Jensen, Emil Wolsk, Jens Jakob Thune, Mette Rauhe Mouridsen, Christian Ditlev Tuxen, Peter Godsk Jørgensen, et al.

  • Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study

    by Casper Binding, Mariam Elmegaard, Simon Larsen, Emma Kidholm Boysen, Marte Austreim, Noor Abassi, Caroline Sindet-Pedersen, Caroline Hartwell Garred, Emil Fosbøl, Anders Holt, et al.

    Background and Aims: Anticoagulation therapy in patients with atrial fibrillation (AF) has changed over time, particularly following the introduction of direct oral anticoagulants. However, it is unknown how the uptake of anticoagulation therapy and the related clinical outcomes in elderly patients with AF have changed over time. Methods: Patients with new-onset AF were included and divided into three age groups: older adults (65–74 years), elderly (75–84 years), and very elderly (≥85 years). Temporal trends in the initiation of oral anticoagulants (OACs), the stroke-free survival, major bleedings including intracerebral haemorrhage (ICH), and all-cause mortality were investigated from 1999 to 2022. Results: In total, 243 938 patients were included, of whom 89 184 (36.6%) were older adults, 99 002 were elderly (40.6%), and 55 752 (22.8%) were very elderly. The proportion of very elderly patients with AF receiving OACs was 71% in 2022. The absolute improvement in the 5-year probability of stroke-free survival was 10.1% in the older adult patients, 12.8% in the elderly patients, and 3.5% in the very elderly patients. The 5-year absolute risk of ICH increased among the elderly and very elderly AF patients. Conclusions: Over the past two decades, the risk of stroke decreased significantly among all age groups, with no subsequent increase in the risk of bleeding among older adults in an era where OACs were almost fully implemented. In the very elderly patients aged ≥85 years, the risk of stroke only slightly improved over time, with an increase in the risk of ICH.


  • Open Access

    Care and outcomes of first-time myocardial infarction among vulnerable populations in Denmark, 2003–22: a nationwide registry-based cohort study

    by Clara Friis, Sofie-Louise Feentved Ødum, Caroline Hartwell Garred, Deewa Zahir Anjum, Marte Austreim, Camilla Fuchs Andersen, Nina Nouhravesh, Emil Fosbøl, Lars Køber, Daniel Mølager Christensen, et al.


  • Open Access

    Associations of Body Mass Index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: A 10-year follow-up study (A NorthStar Substudy)

    by Morten Malmborg, Mohamed El-Chouli, Camilla Fuchs Andersen, Mariam Elmegaard, Caroline Garred, Deewa Zahir, Jawad H Butt, Daniel M Christensen, Nina Nouhravesh, Emil Fosbøl, et al.

    Background Obesity is common in heart failure with reduced ejection fraction (HFrEF). As anti-obesity treatments advance, understanding how body mass index (BMI) affects outcomes in HFrEF is increasingly important. Objective To examine whether a BMI >27 kg/m² is linked to higher risks of all-cause mortality, cardiovascular death, and heart failure (HF) hospitalization in HFrEF patients. Methods This study included 1,017 clinically stable, medically optimized HFrEF patients from the NorthStar study (2005–2009), followed through 2023 using Danish registries. Outcomes were assessed with Cox models adjusted for prognostic factors. The primary endpoint was all-cause mortality; secondary endpoints included cardiovascular death, HF hospitalization, and a composite of mortality or hospitalization. Subgroup analyses compared BMI categories (27 kg/m²). Results Patients with BMI >27 had more diabetes (27.8% vs. 17.7%) and lower NT-proBNP (median 776 vs. 1,163 pg/mL) than those with BMI 24–27, with similar HF etiology. Over a median 8.8 years, 821 patients (80.7%) died, including 444 cardiovascular deaths, and 740 (72.8%) were hospitalized for HF. A BMI of 35 vs. 27 was associated with non-significant increased all-cause mortality (HR 1.18, 95% CI 0.94–1.48) but significantly higher cardiovascular mortality (HR 1.42, 95% CI 1.05–1.92), HF hospitalization (HR 1.33, 95% CI 1.05–1.67), and composite outcome (HR 1.30, 95% CI 1.06–1.60). Subgroup analysis showed higher mortality with BMI >27 vs. 24–27 in ischemic cardiomyopathy (HR 1.31, 95% CI 1.05–1.64), but not in non-ischemic (HR 0.86, 95% CI 0.66–1.12), interaction p=0.015. Conclusion Among HFrEF patients—especially those with ischemic cardiomyopathy—BMI >27 is associated with worse outcomes, challenging the “obesity-survival paradox” and highlighting the importance of effective weight management.

  • Open Access

    Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score

    by Noor K. Abassi, Nina Nouhravesh, Mariam Elmegaard, Marte Austreim, Deewa Zahir, Caroline Hartwell Garred, Jawad H. Butt, Camilla Fuchs Andersen, Jarl E. Strange, Caroline Sindet‐Pedersen, et al.

    Background: Heart failure (HF) and frailty often coexist. However, it is unknown how the interplay between HF and frailty at HF onset impacts prognosis of frail patients with HF and how this has evolved over time. Methods and Results: We identified 131 235 patients with new‐onset HF (median age 74 years, 39.7% women) from Danish nationwide registers in 1999 to 2017. Stratification according to the Hospital Frailty Risk Score resulted in (1) 102 635 (78%) nonfrail, (2) 26 054 (20%) moderately frail, and (3) 2609 (2%) severely frail patients. The proportion of moderately frail patients increased from 13.2% to 24.9%. Five‐year absolute risks of all‐cause mortality, HF hospitalization, and non‐HF hospitalization were calculated using the Kaplan‐Meier and Aalen‐Johansen estimators. From 1999 to 2002 to 2003 to 2017, all‐cause mortality risk (95% CI) declined from 56.4% (55.8%–57.0%) to 33.3% (32.6%–34.1%), 79.8% (78.5%–81.0%) to 58.6% (57.2%–60.1%), and 90.8% (85.6%–96.0%) to 79.8% (76.4%–83.2%) in nonfrail, moderately frail, and severely frail patients, respectively. HF hospitalization risk remained almost constant over the study period. Non‐HF hospitalization risk declined from 74.0% (73.5%–74.5%) to 65.8% (65.0%–66.5%) in nonfrail patients and remained stable overall in moderately frail and severely frail patients over the study period. Conclusions: We observed an increase in frail patients. Mortality decreased for all frailty groups but remained high for severely frail patients. These findings indicate the need for further evidence on the optimization of care for frail patients with HF, and future research should address the development of comprehensive management strategies, integrating frailty assessment into standard clinical care and focused care for older patients with HF.


  • Open Access

    Kidney Status and Events Preceding Death in Heart Failure: A Real-world Nationwide Study

    by Deewa Zahir Anjum, Caroline Hartwell Garred, Nicholas Carlson, Emil Fosbol, Mariam Elmegaard, Pardeep S. Jhund, John J.V. McMurray, Mark C. Petrie, Lars Kober, Morten Schou

    Background Chronic kidney disease (CKD) is a frequent comorbidity in heart failure (HF) patients, affecting prognosis and mortality. This study investigates the relationship between kidney function and adverse kidney events preceding death in HF patients. Methods We analyzed registry data of HF patients who died between 2014 and 2021, with at least one year of HF diagnosis. Adverse kidney events, including acute kidney injury (AKI) and end- stage kidney disease (ESKD), were assessed. Patients were grouped by estimated glomerular filtration rate (eGFR) one year before death: eGFR≥60, eGFR 30-59, and eGFRResults Among 36,435 HF patients who died, 37% had eGFR≥60, 46% had eGFR 30-59, and 17% had eGFRConclusions In HF patients, AKI and ESKD are common in the last year of life, particularly in those with lower baseline eGFR, with kidney decline accelerating in the final months.

  • Open Access

    Temporal trends in mortality, heart failure hospitalization, and stroke in heart failure patients with and without atrial fibrillation: A nationwide study from 1997-2018 on 152,059 patients

    by Marte Austreim, Nina Nouhravesh, Mariam Elmegaard Malik, Noor Kaynat Abassi, Deewa Zahir, Caroline Hartwell Garred, Camilla Fuchs Andersen, Morten Lock Hansen, Jonas Bjerring Olesen, Emil L. Fosbøl, et al.

    Background: Given the many advances in treating heart failure (HF) and atrial fibrillation (AF) separately over the past decades, it remains unclear how the prognosis of patients diagnosed with both conditions has changed over time. We aimed to investigate the temporal trends in clinical outcomes from 1997 to 2018 in patients diagnosed with both HF and AF. Methods: From Danish nationwide registries, we identified 152,059 patients with a first-time HF-diagnosis from 1997 to 2018. Patients were grouped according to year of new-onset HF and AF-status: Prevalent AF (n=34,734), New-onset HF (n=12,691), and No AF (n=104,634). Outcomes of interest were the five-year risk of all-cause mortality, HF-hospitalization, and stroke. Results: Between 1997 and 2018, the proportion of patients with prevalent or new-onset AF increased from 24.7% (n=9256) to 35.8% (n=14,970). The five-year risk of all-cause mortality decreased from 69.1% (95% CI): 67.9%-70.2%) to 51.3% (49.9%-52.7%), 62.3% (60.5%-64.4%) to 43.0% (40.5%-45.5%), and 61.9% (61.3%-62.4%) to 36.7% (35.9%-37.6%) for the prevalent AF, new-onset AF, and no AF group, respectively. Minimal changes were observed in the risk of HF-hospitalization. The five-year risk of stroke decreased from 8.5% (7.8%-9.1%) to 5.0% (4.4%-5.5%) in the prevalent AF group, 8.2% (7.2%-9.2%) to 4.6% (3.7%-5.5%) in the new-onset AF group, and 6.3% (6.1%-6.6%) to 4.9% (4.6%-5.3%) in the no AF group. Simultaneously, patients prescribed anticoagulant therapy within 90 days after HF-onset increased from 42.7% to 93.1% in patients with prevalent AF and 41.9% to 92.5% in patients with new-onset AF. Conclusion: From 1997 to 2018, we observed an increase in patients with HF and coexisting AF. Mortality and stroke risk decreased across all patient groups regardless of AF-status. Anticoagulation therapy increased, and stroke risk in patients with HF and AF was reduced to similar levels as HF patients without AF at the end of the study period. Clinical Perspective: What is new?: In patients with heart failure, an increasing proportion had concomitant atrial fibrillation in 2018 versus 1997. The mortality- and stroke risk decreased for all patients with heart failure over the past two decades, also for patients with coexisting atrial fibrillation, and more patients received guideline-recommended therapy in 2018 versus in 1997. What are the clinical implications?: The increasing trend of patients with heart failure and coexisting atrial fibrillation necessitates a better understanding of the coexistence of these two conditions, of which this study provides insight into the evolving prognosis and management landscape of individuals with both heart failure and atrial fibrillation over the past two decades. Graphical